XENE (Xenon Pharmaceuticals Inc)
Insider Trading Activity
Every open-market purchase and sale reported by XENE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Dawn Svoronos | Director | M | — | — |
| 2026-08-31 | CHRISTOPHER JOHN KENNEY | Chief Medical Officer | Sell | — | — |
| 2026-08-13 | STEVEN GANNON | Director | Sell | — | — |
| 2026-06-08 | Gillian Cannon | Director | Sell | — | — |
| 2026-06-08 | GARY PATOU | Director | Sell | — | — |
| 2026-06-03 | STEVEN GANNON | Director | MIXED | — | — |
| 2026-06-03 | Patrick Machado | Director | M | — | — |
| 2026-06-03 | ELIZABETH A. GAROFALO | Director | M | — | — |
| 2026-06-03 | Gillian Cannon | Director | M | — | — |
| 2026-06-03 | Justin D. Gover | Director | M | — | — |
| 2026-06-03 | Dawn Svoronos | Director | MIXED | — | — |
| 2026-06-03 | GARY PATOU | Director | M | — | — |
| 2026-05-13 | STEVEN GANNON | Director | M | — | — |
| 2026-03-13 | CHRISTOPHER JOHN KENNEY | Chief Medical Officer | MIXED | — | — |
| 2026-03-13 | Andrea DiFabio | Chief Legal Officer | MIXED | — | — |
| 2026-03-13 | IAN MORTIMER | PRESIDENT & CEO | MIXED | — | — |
| 2026-03-11 | Andrea DiFabio | Chief Legal Officer | MIXED | — | — |
| 2026-03-11 | CHRISTOPHER JOHN KENNEY | Chief Medical Officer | MIXED | — | — |
| 2026-03-11 | IAN MORTIMER | PRESIDENT & CEO | MIXED | — | — |
| 2026-01-09 | Darren S Cline | Chief Commercial Officer | A | — | — |
| 2026-01-09 | CHRISTOPHER JOHN KENNEY | Chief Medical Officer | A | — | — |
| 2026-01-09 | IAN MORTIMER | PRESIDENT & CEO | A | — | — |
| 2026-01-09 | Andrea DiFabio | Chief Legal Officer | A | — | — |
| 2026-01-02 | IAN MORTIMER | PRESIDENT & CEO | MIXED | — | — |
| 2025-12-09 | IAN MORTIMER | PRESIDENT & CEO | Sell | — | — |
| 2025-12-03 | IAN MORTIMER | PRESIDENT & CEO | Sell | — | — |
| 2025-10-17 | Thomas Patrick Kelly | Chief Financial Officer | A | — | — |
| 2025-10-01 | IAN MORTIMER | PRESIDENT, CEO & INTERIM CFO | MIXED | — | — |
| 2025-06-24 | Darren S Cline | Chief Commercial Officer | A | — | — |
| 2025-06-06 | Patrick Machado | Director | A | — | — |
| 2025-06-06 | STEVEN GANNON | Director | Sell | — | — |
| 2025-06-06 | Dawn Svoronos | Director | A | — | — |
| 2025-06-06 | ELIZABETH A. GAROFALO | Director | A | — | — |
| 2025-06-06 | Gillian Cannon | Director | A | — | — |
| 2025-06-06 | GARY PATOU | Director | A | — | — |
| 2025-06-06 | Justin D. Gover | Director | A | — | — |
| 2025-05-16 | STEVEN GANNON | Director | M | — | — |
| 2025-03-13 | CHRISTOPHER JOHN KENNEY | Chief Medical Officer | A | — | — |
| 2025-03-13 | IAN MORTIMER | PRESIDENT & CEO | A | — | — |
| 2025-03-13 | Andrea DiFabio | Chief Legal Officer | A | — | — |
| 2025-01-27 | IAN MORTIMER | PRESIDENT & CEO | MIXED | — | — |
| 2024-12-19 | SHERRY AULIN | Chief Financial Officer | MIXED | — | — |
| 2024-11-22 | GARY PATOU | Director | MIXED | — | — |
| 2024-06-05 | Gillian Cannon | Director | A | — | — |
| 2024-06-05 | Dawn Svoronos | Director | A | — | — |
| 2024-06-05 | GARY PATOU | Director | A | — | — |
| 2024-06-05 | Justin D. Gover | Director | A | — | — |
| 2024-06-05 | Patrick Machado | Director | A | — | — |
| 2024-06-05 | ELIZABETH A. GAROFALO | Director | A | — | — |
| 2024-06-05 | STEVEN GANNON | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,018,197 | — |
| — | Director | 444,655 | — |
| — | — | 297,464 | — |
| — | 10%+ Owner | 297,464 | — |
| — | Director | 230,609 | — |
| — | — | 216,694 | — |
| — | Director | 126,311 | — |
| — | Director | 74,225 | — |
| — | Director | 71,770 | — |
| — | PRESIDENT & CEO | 34,223 | — |
| — | Director | 31,373 | — |
| — | Director | 29,798 | — |
| — | 10%+ Owner | 17,680 | — |
| — | EVP, Drug Discovery | 10,000 | — |
| — | Chief Legal Officer | 8,643 | — |
| — | EVP, Strategy & Innovation | 8,398 | — |
| — | VP, Biology | 8,194 | — |
| — | Chief Financial Officer | 7,199 | — |
| — | Director | 7,000 | — |
| — | SVP, Clinical Development | 6,316 | — |
| — | Director | 6,000 | — |
| — | Director | 4,172 | — |
| — | Chief Commercial Officer | 4,000 | — |
| — | Director | 2,645 | — |
| — | Director | 2,645 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the XENE quote page; the site-wide leaderboard is on the insider transactions hub.